Mounjaro, Ozempic, Wegovy, and Saxenda: What the Clinical Trials Measured

The most common confusion is treating a brand name as if it were the molecule itself. Semaglutide is marketed as both Ozempic and Wegovy; tirzepatide as Mounjaro and Zepbound; liraglutide as Saxenda and Victoza. Differences between brands sharing the same active ingredient come down to registered indications and delivery formats, rather than a different underlying compound.

This distinction matters because the scientific literature is cataloged by active ingredient. A study on semaglutide applies to both Ozempic and Wegovy; searching for research strictly by commercial trade name yields only a fraction of what is actually available.

In phase 3 trials conducted in adults with obesity, semaglutide and tirzepatide produced average reductions ranging from approximately 15% to over 20% of body weight over periods of 68 to 72 weeks. These magnitudes are substantially higher than what lifestyle interventions alone achieve in comparable cohorts.

One study design detail rarely makes the headlines: every trial incorporated intensive lifestyle counseling alongside the medication. The published figures reflect pharmacological therapy paired with structured behavioral support, not the drug in isolation.

Liraglutide appears in the literature with smaller effect sizes, though the most notable trial for people who train paired the drug with supervised exercise: this combination outperformed both medication alone and exercise alone in sustaining weight reduction and decreasing body fat.

They do not determine which option is best for an individual. Head-to-head comparisons across molecules remain limited, study populations differ, and selecting a therapy depends on clinical details—such as comorbidities, tolerability, and medical history—that belong in a consultation with your physician, not in a research paper.

Nor do they adequately resolve questions surrounding body composition. Total weight served as the primary endpoint, whereas the breakdown between fat and lean mass comes from secondary analyses and sub-studies, which carry less precision than the headline weight figure implies.

Finally, they do not show what happens in the long run after cessation. That question requires examining extension trials, which tracked weight regain following discontinuation—and those findings are just as critical to read as the primary trials.